{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,25]],"date-time":"2025-10-25T18:57:52Z","timestamp":1761418672349},"reference-count":28,"publisher":"Wiley","issue":"9","license":[{"start":{"date-parts":[[2010,5,24]],"date-time":"2010-05-24T00:00:00Z","timestamp":1274659200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clin Exp Pharma Physio"],"published-print":{"date-parts":[[2010,9]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p>1.\u2002Cyclo\u2010oxygenase (COX)\u20102 inhibitors and other non\u2010steroidal anti\u2010inflammatory drugs (NSAIDs) have been implicated in increased cardiovascular events. However, the direct effects of these drugs on cardiac function have not been explored extensively. Given the important role of the renin\u2013angiotensin\u2013aldosterone system (RAAS) in cardiac remodelling, we sought to determine the effect of COX\u20102 inhibitors and non\u2010specific (NS\u2010) NSAIDs on RAAS\u2010induced cardiac hypertrophy and fibrosis in neonatal rat cardiac myocytes (NCM) and fibroblasts (NCF) isolated from 1\u20132\u2010day\u2010old Sprague\u2010Dawley rat pups.<\/jats:p><jats:p>2.\u2002The NCM were pretreated for 2\u2003h with COX\u20102 inhibitors (celecoxib or rofecoxib) or NS\u2010NSAIDs (naproxen; all at 0.1\u201310\u2003\u03bcmol\/L) before being stimulated with 10\u2003\u03bcmol\/L aldosterone for 72\u2003h or with 0.1\u2003\u03bcmol\/L angiotensin (Ang) II for 60\u2003h. Hypertrophy of NCM was assessed by [<jats:sup>3<\/jats:sup>H]\u2010leucine incorporation.<\/jats:p><jats:p>3.\u2002The NCF were pretreated with COX\u20102 inhibitors or naproxen as described for NCM before being stimulated with 0.1\u2003\u03bcmol\/L AngII for 48\u2003h. Collagen synthesis was subsequently assayed by [<jats:sup>3<\/jats:sup>H]\u2010proline incorporation.<\/jats:p><jats:p>4.\u2002Pooled cryopreserved male and female rat hepatocytes were treated with or without COX\u20102 inhibitors for 1\u2003h before 1\u2003nmol\/L aldosterone (\u223c540\u2003pg\/mL) was added to all wells. Cells were incubated for a further 60\u2003min and culture media harvested by centrifugation. Human hepatic HepG2 cells were treated with compounds with or without serum starvation for 48\u2003h. All cells were pretreated with COX\u20102 inhibitors for 2\u2003h before the addition of aldosterone. Cell culture media were harvested after a further 3, 18, 24 or 48\u2003h incubation. Aldosterone concentrations in the culture media were determined by enzyme immunoassay.<\/jats:p><jats:p>5.\u2002Aldosterone\u2010 and AngII\u2010stimulated NCM hypertrophy was inhibited by celecoxib, but not by rofecoxib or naproxen. In NCF, AngII\u2010stimulated collagen synthesis was inhibited by celecoxib and, to a lesser extent, by rofecoxib, whereas naproxen had no effect. The COX\u20102 inhibitors inhibited aldosterone uptake and\/or metabolism by rat hepatocytes, but had no effect in human hepatic HepG2 cells.<\/jats:p><jats:p>6.\u2002These results demonstrate a potential antiremodelling effect of selective COX\u20102 inhibitors in the setting of RAAS stimulation in cardiac cells, whereas naproxen has no effect.<\/jats:p>","DOI":"10.1111\/j.1440-1681.2010.05405.x","type":"journal-article","created":{"date-parts":[[2010,5,26]],"date-time":"2010-05-26T15:34:29Z","timestamp":1274888069000},"page":"912-918","source":"Crossref","is-referenced-by-count":19,"title":["Celecoxib, but not rofecoxib or naproxen, attenuates cardiac hypertrophy and fibrosis induced <i>in vitro<\/i> by angiotensin and aldosterone"],"prefix":"10.1111","volume":"37","author":[{"given":"Bing H","family":"Wang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Micka C","family":"Bertucci","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jian Yang","family":"Ma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anastasia","family":"Adrahtas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raymond Y","family":"Cheung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Henry","family":"Krum","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2010,8,24]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1001\/archinternmed.2008.525"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1159\/000086459"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.pharmtox.38.1.97"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.carpath.2007.02.005"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1152\/ajpheart.00136.2003"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.yjmcc.2004.04.002"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.106.647230"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.106.675306"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.107.749739"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.30.6.684"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1517\/13543784.7.5.753"},{"key":"e_1_2_6_13_2","first-page":"97","article-title":"Cardioprotection by aldosterone receptor antagonism in heart failure. Part I. The role of aldosterone in heart failure","volume":"31","author":"Dieterich HA","year":"2005","journal-title":"Fiziol. Cheloveka"},{"key":"e_1_2_6_14_2","first-page":"34","article-title":"Blockade of renin\u2013angiotensin\u2013aldosterone system in kidney and heart disease: How much do we need?","volume":"40","author":"Lim S","year":"2008","journal-title":"Acta Med. Indones."},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2006.02678.x"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/0039-128X(90)90024-6"},{"key":"e_1_2_6_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cardfail.2004.03.002"},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.RES.56.6.884"},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M110405200"},{"key":"e_1_2_6_20_2","doi-asserted-by":"publisher","DOI":"10.1152\/ajpheart.01078.2007"},{"key":"e_1_2_6_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/0022-1759(83)90303-4"},{"key":"e_1_2_6_22_2","first-page":"137","article-title":"MTT assays","volume":"43","author":"Supino R","year":"1995","journal-title":"Methods Mol. Biol."},{"key":"e_1_2_6_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0304-3835(02)00003-4"},{"key":"e_1_2_6_24_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.20143"},{"key":"e_1_2_6_25_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.0000135467.43430.16"},{"key":"e_1_2_6_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(07)61295-1"},{"key":"e_1_2_6_27_2","doi-asserted-by":"crossref","first-page":"S747","DOI":"10.1161\/circ.118.suppl_18.S_747","article-title":"Two\u2010year clinical follow\u2010up of COREA\u2010TAXUS trial: Long\u2010term safety and efficacy of celecoxib for 6\u2003months after paclitaxel\u2010eluting stents implantation","volume":"118","author":"Chung JW","year":"2008","journal-title":"Circulation"},{"key":"e_1_2_6_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejheart.2008.02.013"},{"key":"e_1_2_6_29_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI24178"}],"container-title":["Clinical and Experimental Pharmacology and Physiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1440-1681.2010.05405.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1440-1681.2010.05405.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,15]],"date-time":"2023-10-15T23:28:22Z","timestamp":1697412502000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1440-1681.2010.05405.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,8,24]]},"references-count":28,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2010,9]]}},"alternative-id":["10.1111\/j.1440-1681.2010.05405.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1440-1681.2010.05405.x","archive":["Portico"],"relation":{},"ISSN":["0305-1870","1440-1681"],"issn-type":[{"value":"0305-1870","type":"print"},{"value":"1440-1681","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,8,24]]}}}